Background:Mitochondria are the major source of intracellular adenosine triphosphate(ATP)and play an essential role in a plethora of physiological functions,including the regulation of metabolism and the maintenance o...Background:Mitochondria are the major source of intracellular adenosine triphosphate(ATP)and play an essential role in a plethora of physiological functions,including the regulation of metabolism and the maintenance of cellular homeostasis.Mutations of mitochondrial DNA,proteins and impaired mitochondrial function have been implicated in the neurodegenerative diseases,stroke and injury of the central nervous system(CNS).The dynamic feature of mitochondrial fusion,fission,trafficking and turnover have also been documented in these diseases.Perspectives:A major bottleneck of traditional approach to correct mitochondria-related disorders is the difficulty of drugs or gene targeting agents to arrive at specific sub-compartments of mitochondria.Moreover,the diverse nature of mitochondrial mutations among patients makes it impossible to develop one drug for one disease.To this end,mitochondrial transplantation presents a new paradigm of therapeutic intervention that benefits neuronal survival and regeneration for neurodegenerative diseases,stroke,and CNS injury.Supplement of healthy mitochondria to damaged neurons has been reported to promote neuronal viability,activity and neurite re-growth.In this review,we provide an overview of the recent advance and development on mitochondrial therapy.Conclusion:Key parameters for the success of mitochondrial transplantation depend on the source and quality of isolated mitochondria,delivery protocol,and cellular uptake of supplemented mitochondria.To expedite clinical application of the mitochondrial transplantation,current isolation protocol needs optimization to obtain high percentage of functional mitochondria,isolated mitochondria may be packaged by biomaterials for successful delivery to brain allowing for efficient neuronal uptake.展开更多
基金This work was supported by funding from the National Health Research Institutes,Taiwan(Grant numbers:NHRI-EX106-10206NI,NHRI-EX108-10813NI),to Linyi Chen.
文摘Background:Mitochondria are the major source of intracellular adenosine triphosphate(ATP)and play an essential role in a plethora of physiological functions,including the regulation of metabolism and the maintenance of cellular homeostasis.Mutations of mitochondrial DNA,proteins and impaired mitochondrial function have been implicated in the neurodegenerative diseases,stroke and injury of the central nervous system(CNS).The dynamic feature of mitochondrial fusion,fission,trafficking and turnover have also been documented in these diseases.Perspectives:A major bottleneck of traditional approach to correct mitochondria-related disorders is the difficulty of drugs or gene targeting agents to arrive at specific sub-compartments of mitochondria.Moreover,the diverse nature of mitochondrial mutations among patients makes it impossible to develop one drug for one disease.To this end,mitochondrial transplantation presents a new paradigm of therapeutic intervention that benefits neuronal survival and regeneration for neurodegenerative diseases,stroke,and CNS injury.Supplement of healthy mitochondria to damaged neurons has been reported to promote neuronal viability,activity and neurite re-growth.In this review,we provide an overview of the recent advance and development on mitochondrial therapy.Conclusion:Key parameters for the success of mitochondrial transplantation depend on the source and quality of isolated mitochondria,delivery protocol,and cellular uptake of supplemented mitochondria.To expedite clinical application of the mitochondrial transplantation,current isolation protocol needs optimization to obtain high percentage of functional mitochondria,isolated mitochondria may be packaged by biomaterials for successful delivery to brain allowing for efficient neuronal uptake.
